AFECÇÕES DE PELE E SUBCUTÂNEO SECUNDÁRIA AO LÚPUS ERITEMATOSO: CLASSIFICAÇÃO DA LESÕES E ABORDAGEM CLÍNICA DOI Open Access

Isabela Campolina Gonçalves,

Victoria de Lima Campolina,

Shirley Martins Roberto Barbalho

и другие.

Revista Foco, Год журнала: 2024, Номер 17(5), С. e5137 - e5137

Опубликована: Май 16, 2024

Introdução: As afecções de pele e subcutâneo secundárias ao Lúpus Eritematoso são condições dermatológicas complexas que resultam da interação entre fatores genéticos ambientais, desencadeando respostas imunes levam a lesões cutâneas características. A compreensão dessas manifestações é essencial para um diagnóstico preciso tratamento eficaz. Objetivo: Revisar classificar as associadas Eritematoso, fornecendo uma abordagem clínica detalhada auxiliar na identificação, dermatológicas. Metodologia: Realizou-se revisão bibliográfica narrativa, utilizando os descritores MeSH pertinentes selecionando artigos sistemática publicados nos últimos 5 anos. Foram incluídos estudos em inglês, português espanhol, totalizando 31 analisados. Além disso, foram consultados protocolos diretrizes Sociedade Dermatologia embasar discussão. Resultados: Os resultados destacaram classificação das do três subtipos: agudo, subagudo crônico. Cada subtipo apresenta características clínicas, histopatológicas laboratoriais distintas, permitindo melhor propedêutica terapêutica personalizada. identificação precoce doença sistêmica crucial orientar o monitorar efeitos adversos terapias empregadas. Conclusão: multidisciplinar no fundamental avaliação abrangente individualizada cada paciente. dos subtipos permite intervenção mais direcionada eficaz, contribuindo melhoria qualidade vida pacientes. No entanto, necessárias pesquisas aprofundar conhecimento sobre mecanismos patogênicos envolvidos desenvolver inovadoras personalizadas essas complexas.

Bioinformatic analysis of key biomarkers and immune filtration of skin biopsy in discoid lupus erythematosus DOI Open Access
Mengmeng Xiang, Qian Chen, Yang Feng

и другие.

Lupus, Год журнала: 2021, Номер 30(5), С. 807 - 817

Опубликована: Фев. 2, 2021

Objective Discoid lupus erythematosus (DLE) is the most common category of chronic cutaneous erythematosus, where pathological process proved to be closely associated with immunity. This bioinformatic analysis sought identify key biomarkers and perform immune infiltration in skin biopsy samples DLE. Methods GSE120809, GSE100093, GSE72535, GSE81071 were used as data source gene expression profiles, altogether containing 79 DLE 47 normal controls (NC). Limma package was applied differentially expressed genes (DEGs) additional Gene Ontology (GO) together The Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analyses done. Protein-protein interaction network (PPI) constructed using STRING Cytoscape. Hub selected by CytoHubba. Finally, filtration finished CIBERSORT algorithm, comparisons between two groups accomplished. Results A total 391 DEGs identified, which composed 57 up-regulated 334 down-regulated genes. GO KEGG revealed that related different steps response. Top 10 hub included GBP2, HLA-F, IFIT2, RSAD2, ISG15, IFIT1, IFIT3, MX1, XAF1 IFI6. Immune from had found compared NC, higher percentages CD8+ T cells, cells CD4 memory activated, gamma delta, macrophages M1 lower regulatory, M2, dendritic resting, mast activated. Conclusion study contrast NC first research analyze cell

Язык: Английский

Процитировано

12
Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib DOI Creative Commons
Arianna Zhang, Rebecca G. Gaffney, Joseph F. Merola

и другие.

JAAD Case Reports, Год журнала: 2023, Номер 45, С. 110 - 112

Опубликована: Дек. 16, 2023

Язык: Английский

Процитировано

4
Tumid Lupus Erythematosus (TLE): a review of a rare variant of chronic Cutaneous Lupus Erythematosus (cCLE) with emphasis on differential diagnosis DOI Open Access
Maged Daruish, Francesca Ambrogio, Caterina Foti

и другие.

Опубликована: Март 18, 2024

Tumid Lupus Erythematosus has been the subject of heated debate as to its correct nosographic classification. In particular, definition changed over time, depending on different studies performed. this review we address initial TLE, changes that have taken place in understanding and placement within classification (LE), focus clinical, histopathological, immunophenotypical differential diagnosis aspects.

Язык: Английский

Процитировано

1
Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature DOI Creative Commons
Kareem G. Elhage, Raymond Zhao, Mio Nakamura

и другие.

Clinical Cosmetic and Investigational Dermatology, Год журнала: 2022, Номер Volume 15, С. 1815 - 1831

Опубликована: Сен. 1, 2022

Background: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases that present with a wide variety of cutaneous manifestations. In both cases, first-line therapy includes topical corticosteroids. Patients may more widespread disease requiring systemic treatments, including corticosteroids, traditional immunosuppressants, or antimalarials. Due to their complex nature, CLE DM remain difficult treat continue cause significant distress patients. Objective: To summarize the most recent literature on safety efficacy novel treatment modalities for DM. Methods: A search was conducted PubMed using terms “(dermatomyositis) AND (treatment)” “(cutaneous lupus) (treatment)”. Additional included specific names biologic agents, phosphodiesterase inhibitors (apremilast), JAK inhibitors. Results: inhibitors, PDE-4 biologics have shown promise in reducing symptoms DM, reduction SLE Disease Activity Index 2000 (SLEDAI-2K), Lupus Erythematosus Area Severity (CLASI), British Isles Assessment Group (BILAG), Dermatomyositis (CDASI), Score (DAS). Conclusion: While there been advancements further research clinical trials required better elucidate which is best individual Keywords: biologics, erythematosus, dermatomyositis,

Язык: Английский

Процитировано

6
Nano‐encapsulated anandamide reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus DOI Open Access
Erika T McCormick,

Andrew Draganski,

Samantha A. Chalmers

и другие.

Experimental Dermatology, Год журнала: 2023, Номер 32(12), С. 2072 - 2083

Опубликована: Сен. 19, 2023

Abstract Cutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune skin disease which occurs independently and in conjunction with systemic erythematosus. Drug development for CLE severely lacking. Anandamide (AEA) primary endocannabinoid exhibits immunomodulatory effects through mixed cannabinoid receptor agonism. We evaluated AEA as topical treatment assessed benefits of nanoparticle encapsulation (AEA‐NP) on cutaneous drug penetration, delivery biological activity. Compared to untreated controls, AEA‐NP decreased IL‐6 MCP‐1 UVB‐stimulated keratinocytes ( p < 0.05) vitro. In BALB/c mice, displayed improved extended release persistence the follicular unit extending base after 24 h. Utilizing MRL‐lpr murine model, twice weekly lesions 10 weeks led clinical histologic lesion scores compared unencapsulated controls 0.05). Prophylactic application commonly involved areas mice similarly resulted when 0.05), reduced C3 IBA‐1 lesional tissue The demonstrated support its potential therapy CLE. This work also suggests that improves penetration efficacy. Future studies will be conducted assess full therapeutic potential.

Язык: Английский

Процитировано

3
Drug-induced lupus erythematosus DOI Creative Commons

Ana L. Gouveia,

Margarida Gonçalo

Portuguese Journal of Dermatology and Venereology, Год журнала: 2023, Номер 81(3)

Опубликована: Окт. 2, 2023

Drug-induced lupus erythematosus is an autoimmune disease with unexpected onset after treatment certain drugs.Clinically, this very similar to idiopathic erythematosus, although its manifestations are typically milder.In addition, the laboratory and histological changes of induced forms also not significantly different from condition, sometimes making diagnosis drug-induced form a challenge for clinicians.This entity has been gaining relevance in clinical setting number drugs associated it increasing, mainly due emergence new biological therapies strong causal link lupus, such as tumor necrosis factor-alpha inhibitors.However, there still no universally accepted diagnostic criteria identify disease, information about pathophysiology somewhat scarce, difficult predict most likely culprit before enough reports establish link.In some risk factors have shown susceptibility individuals, they yet fully understood.Given possibility reversal by withdrawal offending drug, extremely important be aware possible implication drug pathogenesis clinicians who approach patients manifestations, particularly cutaneous mandatory look used patient.This review will systematize current knowledge terms pathophysiology, clinical, histopathological, diagnosis, treatment, well commonly implicated drugs.

Язык: Английский

Процитировано

3
Bioinformatics analyses of gene expression profile identify key genes and functional pathways involved in cutaneous lupus erythematosus DOI

Zhenyu Gao,

Linchong Su,

Qingchao Wu

и другие.

Clinical Rheumatology, Год журнала: 2021, Номер 41(2), С. 437 - 452

Опубликована: Сен. 23, 2021

Язык: Английский

Процитировано

7
Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Following Rifampicin Treatment: A Case Report DOI Open Access
Ramesh Shrestha,

Shivendra K Jha,

Jasmine Bartaula

и другие.

Cureus, Год журнала: 2021, Номер unknown

Опубликована: Ноя. 3, 2021

Drug reaction with eosinophilia and systemic symptoms (DRESS) is an idiosyncratic severe cutaneous adverse (SCAR) characterized by a skin rash involvement (e.g., hematological, solid organ abnormalities). Various medications, most commonly anticonvulsants (carbamazepine, phenytoin), antibiotics (vancomycin, amoxicillin), sulfa drugs (dapsone, sulfasalazine), have been implicated. We report case of 75-year-old man pulmonary tuberculosis under anti-tubercular treatment (ATT Category 1 as per the national guidelines Nepal) presenting rash, fever, liver dysfunction, eosinophilia, combination features suggestive DRESS. According to (TB) survey 2018-2019, over 117,000 people in Nepal were living TB, including 69,000 newly diagnosed people. In third-world countries, such Nepal, high TB prevalence, Southeast Asian region (with huge percentage global burden ‎TB‎ incidence), risk life-threatening drug reactions during ATT high. However, good response seen if it recognized early on stopping receiving course steroids emollients.

Язык: Английский

Процитировано

6
Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome DOI

Lauren Skudalski,

Neda Shahriari, Kristin Torre

и другие.

Journal of the American Academy of Dermatology, Год журнала: 2022, Номер 87(1), С. 1 - 18

Опубликована: Фев. 22, 2022

Язык: Английский

Процитировано

4
Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: An evidence-based review DOI Open Access
Abrahim Abduelmula, Siddhartha Sood, Asfandyar Mufti

и другие.

Journal of the American Academy of Dermatology, Год журнала: 2023, Номер 89(1), С. 130 - 131

Опубликована: Март 18, 2023

Язык: Английский

Процитировано

2